It seems like diabetes patients are getting all healed as Sanofi meds for such illness drops sales. The company is facing the steepest drop it had in the last five years.
The record was at an eight percent decrease by the start of the week. This causes a huge swipe worth 9.2 billion euros to the overall assets of the company. This could mean that they will have to change the team that is working on the drugs and the marketing strategies.
They are keeping their plans intact for the meantime. This is despite the warnings that the demand for the diabetes drug will continue in the coming months.
They have dealt with this in the past six years. They have driven the business by leveling the losses from their patented drugs to the quality and the sales of their other drugs. These include the Lovenox and Plavix on their list.
The key reason why their diabetes drug, the area that composes fifth of the total earnings of the company, was competition. They were forced to strip down the prices because of the insurance companies and the other drug companies that are offering the same drug.
They already have plans for next year to keep the diabetes problem a more handled and stable one. Meanwhile, they will find the right words to best explain the situation to their investors before they hit the panic button.
